This section highlights FDA-related milestones and regulatory updates for drugs developed by Nektar Therapeutics (NKTR).
Over the past two years, Nektar Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Rezpegaldesleukin, NKTR-255, and NKTR-422. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Rezpegaldesleukin FDA Regulatory Timeline and Events
Rezpegaldesleukin is a drug developed by Nektar Therapeutics for the following indication: For the treatment of atopic dermatitis.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Rezpegaldesleukin
- Announced Date:
- April 20, 2026
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced new results from a blinded 16-week treatment extension period in its Phase 2b REZOLVE-AA study.
AI Summary
Nektar Therapeutics reported new results from a blinded 16-week extension of its Phase 2b REZOLVE‑AA study of rezpegaldesleukin. Thirty-one patients entered the extension: 27 continued twice‑monthly active dosing (14 at 18 µg/kg and 13 at 24 µg/kg) and 4 remained on placebo. Ninety‑four percent of patients completed the extension.
From week 36 to week 52, 29% of patients in the 18 µg/kg arm and 31% in the 24 µg/kg arm achieved a new SALT score ≤20 (about 80% or more scalp hair coverage), versus none in placebo. At week 52, SALT50 responses were 37.7% (low dose) and 38.8% (high dose) compared with 13.6% for placebo. SALT30 responses were 45.6% and 47.6% versus 24.2% for placebo.
The twice‑monthly dosing maintained a favorable safety profile through 52 weeks. Nektar said the results support advancing rezpegaldesleukin into late‑stage development and plans to present the data at a medical conference in 2026.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- March 28, 2026
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver, CO.
AI Summary
Nektar Therapeutics showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. The company presented its findings to dermatology specialists and attendees, bringing its recent clinical and scientific updates to a major professional audience. The presentations increased Nektar’s visibility at a leading dermatology conference and may inform clinicians and investors about the company’s progress.
Separately, Rosen Law Firm reminds anyone who bought Nektar securities between February 26, 2025 and December 15, 2025 that the deadline to seek lead plaintiff status is May 5, 2026. Purchasers during that period may be eligible for compensation through a contingency fee arrangement, meaning no out-of-pocket costs. No class has been certified yet, and you are not represented by counsel unless you retain one. To learn more or join the action, visit the Rosen Law Firm website or contact them by phone or email for details.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- March 20, 2026
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata have been accepted for two oral presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31, 2026, in Denver, CO.
AI Summary
Nektar Therapeutics announced that data from ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata were accepted for two oral presentations at the 2026 American Academy of Dermatology Annual Meeting, March 27–31 in Denver.
Late-Breaking Research Oral (Abstract 79863): “Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin: Phase 2b Efficacy and Safety Results Following 36-Weeks of Therapy in Severe-to-Very-Severe Alopecia Areata,” presented by David Rosmarin, MD, on Saturday, March 28, 2026, 10:36–10:48 AM MST (Bellco Theatre 3e). Poster Oral (Abstract 73858): “Rezpegaldesleukin: Phase 2b Efficacy, Safety, and Baseline Severity–Dependent Treatment Response in Moderate-to-Severe Atopic Dermatitis,” presented by Raj Chovatiya, MD, PhD, on Saturday, March 28, 2026, 11:40–11:45 AM MST (Poster Center 1).
The REZOLVE‑AA primary endpoint is mean percent reduction from baseline in SALT score at Week 36. Key secondaries include proportions achieving absolute SALT ≤30, ≤20, and ≤10, plus an exploratory ClinRO eyebrow and eyelash score.
REZOLVE‑AD began in October 2023 across ~110 global sites (68% Europe, 16% US, 11% Canada, 5% Australia). Key entry criteria included EASI ≥16, BSA ≥10%, and vIGA‑AD ≥3. Rezpegaldesleukin is being developed as a self‑administered injection and is wholly owned by Nektar.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- February 10, 2026
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in patients with moderate-to-severe atopic dermatitis (AD).
AI Summary
Nektar Therapeutics reported positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T‑cell (Treg) biologic for moderate-to-severe atopic dermatitis. At the 24 µg/kg maintenance dose, 71% (monthly) and 83% (quarterly) of patients maintained EASI-75 responses at week 52. vIGA‑AD 0/1 (almost or completely clear) responses were maintained in 85% with monthly dosing and 63% with quarterly dosing.
Both monthly and quarterly schedules showed meaningful improvement across key efficacy endpoints at week 52, including up to a fivefold increase in EASI‑100 (complete clearance) rates. The safety profile was favorable and consistent with prior rezpegaldesleukin findings.
Study investigators said the durability of maintained responses supports moving rezpegaldesleukin into a pivotal Phase 3 program testing both maintenance schedules. Nektar noted the data validate the novel Treg mechanism as a potential best‑in‑class immune modulator and held a conference call and webcast to review the results.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- February 9, 2026
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT.
AI Summary
Nektar Therapeutics will host an investor call and live webcast on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD trial. The study is testing rezpegaldesleukin, an investigational regulatory T‑cell (Treg) proliferator, in patients with moderate-to-severe atopic dermatitis. The company said the results will be released in a morning press release and then presented during the webcast.
Interested participants can access the live webcast at the provided LINK. The session is aimed at investors and stakeholders who want a first look at the main outcomes from the maintenance period of this midstage trial and how rezpegaldesleukin performed over the 36-week timeframe.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- December 16, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator.
AI Summary
Nektar Therapeutics reported topline results from the 36‑week induction period of the Phase 2b REZOLVE‑AA trial of rezpegaldesleukin in 92 patients with severe‑to‑very‑severe alopecia areata. Patients were randomized 3:3:2 to two dose arms (24 µg/kg and 18 µg/kg, subcutaneous every two weeks) or placebo. At Week 36 the mean percent SALT score reductions were 28.2% (24 µg/kg), 30.3% (18 µg/kg) and 11.2% (placebo); these differences narrowly missed statistical significance (p=0.186 and p=0.121).
After excluding four patients with major baseline eligibility violations, the mean reductions were 29.6%, 30.4% and 5.7% (p=0.049 and p=0.042 versus placebo). Key secondary outcomes showed dose‑dependent benefit (SALT30: 48.9%, 45.7%, 19.1%). Rezpegaldesleukin was generally well tolerated, with mostly mild‑to‑moderate adverse events and a 1.4% discontinuation rate. Nektar said the results establish a Phase 3 dose and support planned advancement to Phase 3; extension data through Week 52 will be reported later.Read Announcement
- Drug:
- Rezpegaldesleukin
- Announced Date:
- November 8, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting.
AI Summary
Nektar Therapeutics presented new data from the ongoing REZOLVE-AD Phase 2b study at the ACAAI 2025 meeting on rezpegaldesleukin, a first-in-class IL‑2 pathway agonist designed to boost regulatory T cells. The trial enrolled 393 patients with moderate-to-severe atopic dermatitis; 99 reported a history of asthma with ACQ-5 data through Week 16.
In patients with asthma, rezpegaldesleukin produced statistically significant and clinically meaningful improvements in mean ACQ-5 at Week 16 versus placebo. In those with partly controlled asthma (ACQ-5 ≥0.5, N=53), at least half improved by ≥0.5 points versus 13% on placebo. In the uncontrolled group (ACQ-5 ≥1.5, N=25), placebo-adjusted ACQ-5 reductions ranged 1.0–1.4, and 75% improved ≥0.5 on the 24 μg/kg q2w dose.
The 24 μg/kg q2w regimen also showed significant benefit on atopic dermatitis endpoints at Week 16 (EASI, EASI-75, EASI-90, vIGA-AD 0/1, itch). Crossover data to Week 24 supported a 24‑week induction with improved EASI-75 (60%), vIGA-AD 0/1 (33%), EASI-90 (37%) and itch response (50%).
REZOLVE-AD 52‑week maintenance data are expected Q1 2026. Top-line Phase 2b results in alopecia areata are due December 2025.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- October 22, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, in atopic dermatitis has been accepted for a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting.
AI Summary
Nektar Therapeutics announced that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell proliferator, has been accepted for a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, November 6–10, 2025.
Presentation (Abstract ID: 7005), titled “Rezpegaldesleukin Novel Treg-Inducing Therapy Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial,” will be delivered by Dr. Jonathan Corren on November 8 at 5:33 PM ET in Room W231.
This global study enrolled 393 moderate-to-severe atopic dermatitis patients without prior biologic or JAK treatments. Participants were randomized to three doses of rezpegaldesleukin or placebo for 16 weeks. Responders (EASI-50) entered a maintenance phase with dosing every four or 12 weeks. Key measures included skin severity, itch scores, and immune biomarkers.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- September 18, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.
AI Summary
Nektar Therapeutics shared new results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin at the 2025 EADV Congress in Paris. Rezpegaldesleukin is an IL-2 pathway agonist that boosts regulatory T cells, aiming to rebalance the immune response in atopic dermatitis. After 16 weeks, all treatment arms showed significant improvements in the Eczema Area and Severity Index (EASI) versus placebo, with the high-dose group (24 µg/kg every two weeks) achieving a 61% mean EASI reduction (p<0.001).
Key secondary outcomes also met statistical goals, including EASI-75, Itch Numerical Rating Scale, and vIGA-AD scores. Patient quality-of-life measures, such as the Dermatology Life Quality Index, improved significantly with high-dose therapy. Interim open-label data for patients who crossed over from placebo to high-dose rezpegaldesleukin show further gains by week 24: EASI-75 deepened to 62% and clear or almost clear skin (vIGA-AD 0/1) rose to 38%.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- September 9, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy of Dermatology and Venereology (EADV) Congress being held in Paris, France from September 17-20, 2025.
AI Summary
Nektar Therapeutics announced it will present results from its ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, September 17–20.
The oral presentation will report primary and secondary endpoints from the 16-week induction phase, including several patient-reported outcome assessments. It will also feature new data on participants who crossed over from placebo to high-dose rezpegaldesleukin and remain on treatment.
Abstract ID LBA-108 is titled “Efficacy and Safety of Rezpegaldesleukin, A Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from the 16-Week Induction of a Randomized Phase 2b Study (REZOLVE-AD).” Dr. Jonathan Silverberg will present on Thursday, September 18 at 14:45 in Paris Nord (Session D2T01.3C).
After the congress, the presentation will be available on Nektar’s website under Scientific Publications.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- July 29, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of severe-to-very severe alopecia areata (AA) in adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms.
AI Summary
Nektar Therapeutics announced that the FDA granted Fast Track designation for rezpegaldesleukin to treat severe-to-very severe alopecia areata in patients 12 years and older weighing at least 40 kg. Rezpegaldesleukin is a biologic that stimulates regulatory T cell proliferation by targeting the interleukin-2 receptor. Early trials showed it safely and dose-dependently increased these cells, which regulate immune responses.
The Fast Track status qualifies rezpegaldesleukin for more frequent FDA meetings, rolling reviews, and priority review to accelerate development. Nektar plans to report topline Phase 2b REZOLVE-AA data in December 2025. This study enrolls about 90 patients and assesses changes in the Severity of Alopecia Tool (SALT) score over 36 weeks. The designation underscores the urgent need for new treatments in this chronic hair-loss condition.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- June 24, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin, an IL-pathway agonist and regulatory T-cell (Treg) proliferator.
AI Summary
Nektar Therapeutics announced statistically significant data from the 16‑week induction period of its ongoing Phase 2b REZOLVE‑AD study evaluating rezpegaldesleukin, an investigational IL‐pathway agonist that boosts regulatory T cells. The study, conducted in patients with moderate‑to‑severe atopic dermatitis, showed that all doses of rezpegaldesleukin produced a significantly greater reduction in the Eczema Area and Severity Index (EASI) score compared to placebo. Key secondary endpoints—including achieving 75% and 90% improvement in EASI scores, reducing itch, and improvements in other clinical measures—were also met.
The trial results indicate a rapid onset of action, with early symptom relief after only a few doses. Additionally, the dose‑dependent reduction in inflammatory biomarkers supports rezpegaldesleukin’s potential as a first and best‑in‑class immune modulator. Nektar plans to continue evaluating the drug’s long‑term benefits in later stages of the study.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- June 23, 2025
- Target Action Date:
- June 24, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced it will host an investor call and live webcast to review top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, June 24, 2025 at 8:15am ET / 5:15am PT.
AI Summary
Nektar Therapeutics announced it will host an investor call and live webcast on Tuesday, June 24, 2025, at 8:15am ET (5:15am PT) to present top-line data from the 16-week induction period of its global Phase 2b REZOLVE-AD clinical trial. The trial is studying rezpegaldesleukin, a novel regulatory T-cell (Treg) proliferator, as an investigational treatment for moderate-to-severe atopic dermatitis. The data release aims to update investors on the progress of this innovative immunotherapy, which targets the underlying immune dysfunction linked to the condition. Details on how to access the live webcast will be provided in the morning press release and on the Nektar website. Additionally, a replay will be available for at least 30 days after the event to ensure that all interested parties can review the results and insights presented during the session.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- February 26, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics nnounced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
AI Summary
Nektar Therapeutics announced that it has successfully completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin for patients with severe-to-very-severe alopecia areata. The trial enrolled 84 patients who have not previously received a JAK inhibitor or other biologic treatment. Rezpegaldesleukin is an investigational biologic that works by targeting the interleukin-2 receptor complex in the body to stimulate regulatory T cells, which are important for controlling immune responses. This study aims to evaluate the potential of rezpegaldesleukin to reduce hair loss as measured by the Severity of Alopecia Tool (SALT) score, with further analysis on the percentage of patients achieving significant improvements during the 36-week induction period. The trial has enrolled patients from around the world, including sites in Poland, Canada, and the United States, and topline data is expected later this year.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- February 10, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
AI Summary
Nektar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational biologic therapy, rezpegaldesleukin, for treating moderate-to-severe atopic dermatitis in patients ages 12 and older. This designation is intended for treatments that address serious conditions and unmet medical needs, allowing for more frequent interactions with the agency and an expedited review process. Rezpegaldesleukin works by targeting the interleukin-2 receptor complex, which helps stimulate regulatory T cells that can balance the immune response. The therapy is aimed at patients whose condition is not adequately managed by topical prescription treatments or for whom those treatments are not advisable. This Fast Track status highlights the potential of rezpegaldesleukin to offer a new treatment option for both adult and pediatric patients suffering from this challenging skin disorder.
Read Announcement- Drug:
- Rezpegaldesleukin
- Announced Date:
- January 10, 2025
- Indication:
- For the treatment of atopic dermatitis.
Announcement
Nektar Therapeutics announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.
AI Summary
In January 2025, Nektar Therapeutics announced that it has reached its target enrollment for the REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. The trial enrolled 396 patients across about 110 global sites, with the majority of enrollments coming from Europe. Rezpegaldesleukin is designed as a first-in-class interleukin-2 receptor agonist that works by stimulating regulatory T cells, potentially restoring balance to the immune system and reducing inflammation in the skin.
Early clinical results have shown that the treatment increases Tregs safely and produces promising, dose-dependent improvements in skin outcomes. The study will measure changes using the Eczema Area and Severity Index over a 16-week induction period, with topline data expected in the second quarter of 2025, potentially offering a new treatment option for those affected by this chronic condition.
Read Announcement
NKTR-255 FDA Regulatory Events
NKTR-255 is a drug developed by Nektar Therapeutics for the following indication: NKTR-255 is designed to enhance functional NK cell populations.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- NKTR-255
- Announced Date:
- December 7, 2024
- Indication:
- NKTR-255 is designed to enhance functional NK cell populations
Announcement
Nektar Therapeutics announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL) at the 66th ASH Annual Meeting and Exposition in San Diego, California.
AI Summary
Nektar Therapeutics announced positive results from its Phase 2 proof-of-concept study, presented at the 66th ASH Annual Meeting in San Diego. The study evaluated NKTR-255 as an additional treatment alongside CD19-directed CAR-T therapy in patients with relapsed/refractory Large B-cell Lymphoma. Patients who received NKTR-255 reached a 73% complete response rate at six months, compared to 50% in the placebo group. The treatment also showed enhanced CAR T-cell activity by significantly boosting the CD8+ T cells early after administration. NKTR-255 is an investigational IL-15 agonist that works by activating and expanding immune cells, including natural killer cells and CD8+ T cells, to improve both the level and duration of the cancer response. These findings suggest that the use of NKTR-255 could strengthen the durability of responses in patients undergoing CAR-T therapy for LBCL.
Read Announcement
NKTR-422 FDA Regulatory Events
NKTR-422 is a drug developed by Nektar Therapeutics for the following indication: For autoimmune Disorders.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- NKTR-422
- Announced Date:
- November 18, 2024
- Indication:
- For autoimmune Disorders
Announcement
Nektar Therapeutics announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR) conference, being held in Washington, D.C. from November 14-19, 2024.
AI Summary
Nektar Therapeutics is set to present key preclinical data on its novel CSF-1R agonist, NKTR-422, at the 2024 American College of Rheumatology (ACR) conference in Washington, D.C. from November 14-19, 2024. The presentation, scheduled for November 18 at 3:15 PM EST, will focus on how NKTR-422 fosters inflammation resolution and promotes tissue repair in chronic inflammatory conditions. Unlike currently approved therapies that do not fully restore tissue health, NKTR-422 is engineered to selectively target and reprogram tissue-resident macrophages, leading to sustained activity from a single dose. Data from multiple preclinical models show that the drug can accelerate treatment efficacy, particularly when used alongside standard inflammatory cytokine blockade. This oral presentation is an important step in evaluating NKTR-422’s potential to improve clinical outcomes in conditions characterized by inflammation and tissue damage.
Read Announcement
